Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Economic Burden of Prostate Cancer in Iran: Measuring Costs and Quality of Life
Fatemeh Soleymani
Fatemeh Soleymani

Associate Professor of Pharmacoeconomics and Pharmaceutical Administration

Department Pharmacoeconomics and Pharmaceutical Administration

School of Pharmacy

Pharmaceutical Management & Economics Research Center

Tehran University of Medical Sciences

Related Documents
1. Cost-Utility Analysis of Lenvatinib Vs. Sorafenib in Unresectable Hepatocellular Carcinoma in Iran, Expert Review of Pharmacoeconomics and Outcomes Research (2025)
All Documents
1. Cost-Effectiveness Analysis of Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis: A Systematic Review and Meta-Analysis, Expert Review of Pharmacoeconomics and Outcomes Research (2025)
2. Cost-Utility Analysis of Combination Medical Therapies in Chronic Coronary Syndrome: A Comparative Study Using Real-World and Patient-Level Data From Iran, BMJ Open (2025)
3. Cost-Utility Analysis of Combination Medical Therapies in Chronic Coronary Syndrome: A Comparative Study Using Real-World and Patient-Level Data From Iran, BMJ Open (2025)
4. Cost-Utility Analysis of Lenvatinib Vs. Sorafenib in Unresectable Hepatocellular Carcinoma in Iran, Expert Review of Pharmacoeconomics and Outcomes Research (2025)
5. Empowering the Pharmaceutical Industry by Revolutionizing Education, DARU, Journal of Pharmaceutical Sciences (2025)
6. Trends Analysis and Future Study of the Pharmaceutical Industry Field: A Scoping Review, DARU, Journal of Pharmaceutical Sciences (2025)
7. Availability and Affordability of Selected Medicines in the Islamic Republic of Iran; [Disponibilite Et Accessibilite Economique De Certains Medicaments En Republique Islamique D’Iran], Eastern Mediterranean Health Journal (2024)
8. Choosing the Best Instrument for Measuring Health Spillover Effect in Caregivers of Patients With Multiple Sclerosis, Value in Health Regional Issues (2024)
9. Cost-Utility Analysis of Erenumab Compared to Topiramate for Preventive Therapy of Migraine in Iran, Iranian Journal of Pharmaceutical Research (2024)
10. Pesticide Residues in Drinking Water Treatment Plants and Human Health Risk Assessment: A Case Study From Northern Iran, Environmental Geochemistry and Health (2024)
11. Regorafenib Versus Cetuximab Plus Irinotecan in Third-Line Metastatic Colorectal Cancer in Iran: A Model-Based Cost-Utility Analysis, Middle East Journal of Cancer (2024)
12. Antibiotic Resistance Clinical Research in Iran: A Scoping Review, Archives of Clinical Infectious Diseases (2023)
13. Prevalence of Comorbidities in Patients With Multiple Sclerosis Using Administrative Data From 2007 to 2016 in Iran, Multiple Sclerosis and Related Disorders (2023)
14. Understanding Conflicts of Interest in Rational Drug Prescription in a Developing Country: A Stakeholder Analysis, Healthcare Guidelines and Ethical Public Health Issues, Journal of Preventive Medicine and Hygiene (2023)
15. Utilization Patterns of Cardiovascular Medications in Patients With Diabetes Mellitus; a Retrospective Cross-Sectional Study, 2013-17, DARU# Journal of Pharmaceutical Sciences (2023)
16. An Assessment of Trends in the Iranian Pharmaceutical Market Following Domestic Production of Selected Medications (2007‒2017) and New Considerations for Health Policymakers, GaBI Journal (2021)
17. Cost-Utility and Budget Impact Analysis of Adding-On Apremilast to Biologic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis, an Iranian Payer Perspective, Research in Pharmaceutical Sciences (2021)
18. Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride, Iranian Journal of Pharmaceutical Research (2021)
19. Antibiotics Prescription Pattern and Their Financial Burden Before and After Intervention in Traumatic Injuries, Trauma Monthly (2020)
20. Fixed Dose Drug Combinations–Are They Pharmacoeconomically Sound? Findings and Implications Especially for Lower- and Middle-Income Countries, Expert Review of Pharmacoeconomics and Outcomes Research (2020)
21. Why Healthcare Market Needs Government Intervention to Improve Access to Essential Medicines and Healthcare Efficiency: A Scoping Review From Pharmaceutical Price Regulation Perspective, Journal of Pharmaceutical Health Services Research (2020)
22. Effectiveness of Audit and Feedback in Addressing Over Prescribing of Antibiotics and Injectable Medicines in a Middle-Income Country: An Rct, DARU# Journal of Pharmaceutical Sciences (2019)
23. Evaluation of Urban and Rural Family Physician Program in Iran: A Systematic Review, Iranian Journal of Public Health (2019)
24. Prescribing Patterns of Physicians Working in Both the Direct and Indirect Treatment Sectors in Iran; Findings and Implications, Journal of Pharmaceutical Health Services Research (2019)
25. Rational Medicine Prescription Interventions in Various Countries: A Systematic Review, Family Medicine and Primary Care Review (2019)
26. Pattern of Antidepressant Utilization and Cost in Iran From 2006 to 2013 in Comparison With Other Countries, Journal of Epidemiology and Global Health (2018)
27. Relationship Between the Provision of Injection Services in Ambulatory Physician Offices and Prescribing Injectable Medicines, Iranian Journal of Pharmaceutical Research (2017)
28. Improving Injectable Medicines Prescription in Outpatient Services: A Path Towards Rational Use of Medicines in Iran, International Journal of Health Policy and Management (2016)